PE20131411A1 - Anticuerpos contra la tweak humana y usos de los mismos - Google Patents

Anticuerpos contra la tweak humana y usos de los mismos

Info

Publication number
PE20131411A1
PE20131411A1 PE2013000786A PE2013000786A PE20131411A1 PE 20131411 A1 PE20131411 A1 PE 20131411A1 PE 2013000786 A PE2013000786 A PE 2013000786A PE 2013000786 A PE2013000786 A PE 2013000786A PE 20131411 A1 PE20131411 A1 PE 20131411A1
Authority
PE
Peru
Prior art keywords
seq
antibodies against
against human
human tweak
chain
Prior art date
Application number
PE2013000786A
Other languages
English (en)
Inventor
Monika Baehner
Hendrik Knoetgen
Jens Niewoehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20131411A1 publication Critical patent/PE20131411A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)

Abstract

REFERIDO A ANTICUERPOS CONTRA LA TWEAK HUMANA, CARACTERIZADO POR TENER COMO DOMINIO VARIABLE DE CADENA LARGA QUE CONTIENE UNA REGION CDR3H ELEGIDA DEL GRUPO FORMADO POR LAS SEQ ID NO: 8, 16 Y 24. TAMBIEN COMPRENDE UNA VARIANTE QUIMERICA EN EL EPITOPE DE LAS CELULAS T DE UN ANTICUERPO QUE CONTIENE UNA CADENA CORTA VARIABLE DE SEQ ID NO: 1, 9, 17 ENTRE OTROS Y UNA CADENA LARGA VARIABLE DE SEQ ID NO: 5, 13, 21 ENTRE OTROS. ASI MISMO CONTIENE: CDR1H DE SEQ ID NO: 6, 14, 22; CDR2H DE SEQ ID NO: 7, 15, 23; CDR3H DE SEQ ID NO: 8, 16, 24 Y CDR1L DE SEQ ID NO: 2, 10, 18; CDR2L DE SEQ ID NO: 3, 11, 19; CDR3L 4, 12, 20. DICHO ANTICUERPO ES UTIL PARA EL TRATAMIENTO DE CANCER, ENFERMEDADES AUTOIMUNES ENTRE OTRAS.
PE2013000786A 2010-10-05 2011-09-30 Anticuerpos contra la tweak humana y usos de los mismos PE20131411A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10186536 2010-10-05

Publications (1)

Publication Number Publication Date
PE20131411A1 true PE20131411A1 (es) 2013-12-16

Family

ID=43086385

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000786A PE20131411A1 (es) 2010-10-05 2011-09-30 Anticuerpos contra la tweak humana y usos de los mismos

Country Status (21)

Country Link
US (1) US9187564B2 (es)
EP (1) EP2625200A1 (es)
JP (1) JP5941049B2 (es)
KR (1) KR101584416B1 (es)
CN (1) CN103154029B (es)
AR (1) AR083336A1 (es)
AU (1) AU2011311673B2 (es)
BR (1) BR112013007293A2 (es)
CA (1) CA2809632A1 (es)
CL (1) CL2013000901A1 (es)
CR (1) CR20130108A (es)
EA (1) EA201300418A1 (es)
EC (1) ECSP13012542A (es)
HK (1) HK1186195A1 (es)
MA (1) MA34642B1 (es)
MX (1) MX343114B (es)
NZ (1) NZ607588A (es)
PE (1) PE20131411A1 (es)
SG (1) SG188605A1 (es)
TW (1) TWI482630B (es)
WO (1) WO2012045671A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5550799B2 (ja) * 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用
CN102793921A (zh) 2002-04-09 2012-11-28 比奥根艾迪克Ma公司 用于治疗tweak 相关病症的方法
EP2332408B1 (en) 2005-02-17 2013-11-13 Biogen Idec MA Inc. Treating neurological disorders
ES2432564T3 (es) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
AU2013244999A1 (en) 2012-04-05 2014-09-25 F. Hoffmann-La Roche Ag Bispecific antibodies against human TWEAK and human IL17 and uses thereof
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
WO2015051234A2 (en) * 2013-10-04 2015-04-09 Biogen Idec Ma Inc. Tweak antagonists for treating lupus nephritis and muscle atrophy
EP3174897B1 (en) * 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
CN112180100A (zh) * 2020-09-27 2021-01-05 西安交通大学 Tweak作为鉴别不同类型银屑病的分子标志物的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
JP3537535B2 (ja) 1994-07-14 2004-06-14 株式会社中埜酢店 免疫グロブリンｇ結合糖鎖構造に基づく臨床検査方法
AU7668696A (en) 1995-11-03 1997-05-22 Austin Research Institute, The Methods and compositions for the reduction of xenotransplantation rejection
DE69734397T2 (de) 1996-08-07 2006-07-06 Biogen Idec Ma Inc., Cambridge Tumor-nekrose-faktor ähnliches ligand
WO1998033523A1 (en) 1997-01-31 1998-08-06 Biovation Limited Vaccination methods and molecules
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
BRPI9910332B8 (pt) 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
JP5550799B2 (ja) 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用
CN102793921A (zh) 2002-04-09 2012-11-28 比奥根艾迪克Ma公司 用于治疗tweak 相关病症的方法
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
WO2006052926A2 (en) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death
CN105535967B (zh) 2005-02-15 2022-05-03 杜克大学 抗cd19抗体及其在肿瘤学中的应用
EP2332408B1 (en) 2005-02-17 2013-11-13 Biogen Idec MA Inc. Treating neurological disorders
US20090068102A1 (en) 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
CN102225200A (zh) 2005-03-07 2011-10-26 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
ES2432564T3 (es) 2005-05-10 2013-12-04 Biogen Idec Ma Inc. Tratamiento y evaluación de trastornos inflamatorios
ES2507069T3 (es) 2005-05-27 2014-10-14 Biogen Idec Ma Inc. Anticuerpos de unión a TWEAK
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
EP1904101A4 (en) 2005-06-08 2011-06-15 Univ Duke ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION
US8097703B2 (en) 2005-06-20 2012-01-17 Medarex, Inc. CD19 antibodies and their uses
CA2619825A1 (en) 2005-08-19 2007-03-01 Centocor, Inc. Proteolysis resistant antibody preparations
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
DE102005060813A1 (de) 2005-12-20 2007-06-28 Rheinisch-Westfälische Technische Hochschule Aachen Selektive Markierung der Glykane von Antikörpern mit modifizierten Nukleotidzuckern als Substrate von rekombinanten Galactosyltransferasen
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
AU2007317755A1 (en) 2006-10-27 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
JP2013543383A (ja) 2013-12-05
WO2012045671A1 (en) 2012-04-12
US20120121583A1 (en) 2012-05-17
MA34642B1 (fr) 2013-11-02
EP2625200A1 (en) 2013-08-14
AU2011311673B2 (en) 2015-09-17
JP5941049B2 (ja) 2016-06-29
TWI482630B (zh) 2015-05-01
MX2013003592A (es) 2013-05-31
AR083336A1 (es) 2013-02-21
TW201219054A (en) 2012-05-16
EA201300418A1 (ru) 2013-09-30
SG188605A1 (en) 2013-04-30
CA2809632A1 (en) 2012-04-12
HK1186195A1 (zh) 2014-03-07
KR20130062369A (ko) 2013-06-12
ECSP13012542A (es) 2013-06-28
CL2013000901A1 (es) 2013-11-29
NZ607588A (en) 2014-02-28
US9187564B2 (en) 2015-11-17
CN103154029B (zh) 2015-11-25
BR112013007293A2 (pt) 2016-06-14
KR101584416B1 (ko) 2016-01-13
CN103154029A (zh) 2013-06-12
CR20130108A (es) 2013-04-29
MX343114B (es) 2016-10-25
AU2011311673A1 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
PE20131411A1 (es) Anticuerpos contra la tweak humana y usos de los mismos
AR074756A1 (es) Anticuerpos contra la angiopoyetina-2 humana
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
PE20141560A1 (es) Anticuerpo anti-epirregulina humanizado y agente terapeutico contra el cancer que comprende dicho anticuerpo como ingrediente activo
PE20140247A1 (es) Anticuerpos anti-cd38
PE20141017A1 (es) Anticuerpos del cea
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PE20140230A1 (es) Anticuerpos para el receptor del factor de crecimiento epidermico 3(her3)
AR124676A2 (es) Formulación farmacéutica que comprende una droga biofarmacéutica
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
CR20120215A (es) Anticuerpos contra csf-1r humano y usos de los mismos
PE20142046A1 (es) Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
UY32451A (es) Moléculas de anticuerpo con especifidad por el ox40 humano
EA032929B1 (ru) Нейтрализующее вирус иммунодефицита человека антитело и способы его применения
PE20141546A1 (es) Anticuerpos anti-cd134(ox40) y sus usos de los mismos
PE20131209A1 (es) Anticuerpos anti-fap
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
PE20142422A1 (es) Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
EA201490850A1 (ru) Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
AR080301A1 (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
AR091703A1 (es) Anticuerpos e inmunoconjugados que comprenden anticuerpos anti-cd22
GT201100023A (es) Anticuerpos neutralizantes del virus anti - influenza a y usos de los mismos

Legal Events

Date Code Title Description
FC Refusal